The decrease in tTG IgA levels might reflect: (i) the removal of the diseased liver, which may have been the target for tTG IgA antibodies or part of a nonspecific humoral response in cirrhosis that normalised after allograft tolerance (false‐positive test); (ii) the effect of immunosuppressive drugs used to prevent allograft rejection, which may have suppressed tTGA/EMA levels, particularly in cases of true CeD (characterised by higher tTGA titers and positive EMA). Here, CD79A is linked to cranioectodermal dysplasia.